The full universe. 517 verified biotech investors, sortable and searchable.
The companion data layer to The Biotech Capital Report. All 517 verified equity investors meeting the n≥5 threshold across the 11-year observation window (2015-2026). Search by firm name. Filter by tier, investor type, or sample-size confidence. Click any row for the underlying numbers and structural context.
Tier 1 firms re-up in 50% or more of their portfolio. Tier 2 covers 30-49%. Tier 3 sits below 30%. Sample-size confidence is tagged on every row. Limited-sample rows (n=5-9) are flagged in the Sample column to reflect lower statistical reliability.
Tier
Type
Sample
Showing 517 of 517
FirmTypeSampleNExit %FO %
Reading the table. Follow-on rate is the percentage of a firm's portfolio companies in which they participated in two or more financing rounds within the 2015-2026 window. Exit rate is the percentage of portfolio companies with status Acquired or Public, computed across all years. Sample-size tag indicates portfolio breadth in the analytical window. Limited-sample rows (n=5-9) are flagged in the Sample column to reflect lower statistical reliability — a single different outcome materially shifts the rate. Click any row for the structural detail.
GO DEEPER
Need this sliced for your company?
On request, we produce custom reports — by modality, therapeutic area, technology platform, and stage. Read the full analysis, or the methodology behind these tiers.
